Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q4 2018 · 10-K
Revenue$0.00$0.00−100.0% vs Q4 2017 Net Income-$14.90M-$14.90MN/M vs Q4 2017 EPS Diluted-$0.62-$0.62N/M vs Q4 2017 Operating Income-$15,305,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,403,000N/M ended Dec 31, 2018 · filed Mar 7, 2019 · 66 d after period end